Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein*
暂无分享,去创建一个
G Vassart | F Libert | R. Doms | M. Parmentier | F. Baleux | C. Blanpain | J. Rucker | G. Vassart | B. Doranz | C. Govaerts | F. Libert | C Blanpain | M Parmentier | I. Migeotte | B J Doranz | J Vakili | J Rucker | C Govaerts | S S Baik | O Lorthioir | I Migeotte | F Baleux | R W Doms | J. Vakili | O. Lorthioir | S. Baik
[1] K. Arai,et al. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat , 1988, Molecular and cellular biology.
[2] R. Mark,et al. Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. , 1992, The Journal of biological chemistry.
[3] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[4] C. Hébert,et al. Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. , 1994, The Journal of biological chemistry.
[5] R. Connor,et al. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.
[6] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[7] Marc Parmentier,et al. Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.
[8] J J Goedert,et al. Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.
[9] M. Goldsmith,et al. Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.
[10] M. Baggiolini,et al. HIV blocked by chemokine antagonist , 1996, Nature.
[11] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[12] I. Charo,et al. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. , 1996, The Journal of biological chemistry.
[13] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[14] G Vassart,et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. , 1996, Biochemistry.
[15] Jennifer C. Lee,et al. CXC Chemokines Bind to Unique Sets of Selectivity Determinants That Can Function Independently and Are Broadly Distributed on Multiple Domains of Human Interleukin-8 Receptor B , 1996, The Journal of Biological Chemistry.
[16] R. Doms,et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[17] C. Katlama,et al. HIV-1 infection in an individual homozygous for CCR5▵32 , 1997, The Lancet.
[18] J J Goedert,et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.
[19] H. Sheppard,et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression , 1997, Nature Medicine.
[20] R. Doms,et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1 , 1997, Journal of virology.
[21] Nancy Sullivan,et al. CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.
[22] C. Mackay,et al. Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.
[23] J. Sodroski,et al. CD4-independent binding of SIV gp120 to rhesus CCR5. , 1997, Science.
[24] J. Sodroski,et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia , 1997, Nature.
[25] S. Rees,et al. A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. , 1997, Analytical biochemistry.
[26] T. Schwartz,et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.
[27] B. Cullen,et al. HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.
[28] R. Doms,et al. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.
[29] R. Doms,et al. Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. , 1997, Methods in enzymology.
[30] J. Mascola,et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression , 1997, Nature Medicine.
[31] R. Doms,et al. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] Marc Parmentier,et al. The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.
[33] B. Bennetts,et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele , 1997, Nature Medicine.
[34] E. Fenyö,et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.
[35] I. Charo,et al. The Amino-terminal Domain of CCR2 Is Both Necessary and Sufficient for High Affinity Binding of Monocyte Chemoattractant Protein 1 , 1997, The Journal of Biological Chemistry.
[36] P. Murphy,et al. Determinants of HIV-1 Coreceptor Function on CC Chemokine Receptor 3 , 1997, The Journal of Biological Chemistry.
[37] J. Sodroski,et al. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. , 1998, Cellular immunology.
[38] J. Westwick,et al. Chemokines: understanding their role in T-lymphocyte biology. , 1998, The Biochemical journal.
[39] D. Kwon,et al. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. , 1998, Virology.
[40] J. Grivel,et al. Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines. , 1998, The Journal of clinical investigation.
[41] M. Wainberg,et al. Effect of HIV constructs containing protease‐reverse transcriptase fusion proteins on viral replication , 1998, AIDS.
[42] S. Kunkel,et al. Novel roles for chemokines and fibroblasts in interstitial fibrosis. , 1998, Kidney international.
[43] W. Gong,et al. Monocyte Chemotactic Protein-2 Activates CCR5 and Blocks CD4/CCR5-mediated HIV-1 Entry/Replication* , 1998, The Journal of Biological Chemistry.
[44] M. Baggiolini. Chemokines and leukocyte traffic , 1998, Nature.
[45] R. Terkeltaub,et al. Chemokines and atherosclerosis. , 1998, Current opinion in lipidology.
[46] R. Strieter,et al. Tumor angiogenesis is regulated by CXC chemokines. , 1998, The Journal of laboratory and clinical medicine.
[47] J. Sodroski,et al. A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5 , 1998, Journal of Virology.
[48] S. O’Brien,et al. Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32 , 1998, Journal of Virology.
[49] Bryan R. Cullen,et al. Multiple Residues Contribute to the Inability of Murine CCR-5 To Function as a Coreceptor for Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates , 1998, Journal of Virology.
[50] John P. Moore,et al. Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[51] P. S. Kim,et al. HIV Entry and Its Inhibition , 1998, Cell.
[52] C. Power,et al. Definition, function and pathophysiological significance of chemokine receptors. , 1998, Trends in pharmacological sciences.
[53] D. Littman. Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.
[54] William C. Olson,et al. Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.
[55] Ying Sun,et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.
[56] H. Guy,et al. Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.
[57] Joseph Sodroski,et al. Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.
[58] R. Doms,et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. , 1999 .
[59] R. Maki,et al. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. , 1999, Trends in pharmacological sciences.
[60] D. Weissman,et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[61] D. Littman,et al. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. , 1999, Science.
[62] R. Doms,et al. HIV and SIV gp120 binding does not predict coreceptor function. , 1999, Virology.
[63] N. Skelton,et al. Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. , 1999, Structure.
[64] M. Essex,et al. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[65] O. Nishimura,et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Doms,et al. Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains , 1999, Journal of Virology.